Form 4: BioMarin Director David Pyott Reports Acquisition of Restricted Stock Units

Director David E.I. Pyott reports the acquisition of 4,720 restricted stock units in BioMarin Pharmaceutical Inc.

Summary

• David E.I. Pyott, a director of BioMarin Pharmaceutical Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 4,720 shares of common stock on May 21, 2024, through the grant of restricted stock units.
• Following the transaction, Pyott directly owns 49,750 shares of BioMarin common stock.
• Pyott has granted power of attorney to G. Eric Davis, Tae Sang Yoo, and Eric Fleekop to execute filings on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock unit grants, indicating standard compensation practices.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their own company's stock. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The acquisition of restricted stock units by a director can positively influence shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates